But in 2017, three randomized controlled trials comparing levosimendan with placebo on top of standard care in cardiac surgical patients failed to reach statistical significance.
← all excerpts
Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.
1
—
—